Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,739
Closed -$625K 67
2024
Q1
$625K Sell
4,739
-6,117
-56% -$754K 0.26% 46
2023
Q4
$1.18M Buy
10,856
+3,249
+43% +$337K 0.42% 43
2023
Q3
$783K Sell
7,607
-616
-7% -$66.4K 0.35% 43
2023
Q2
$949K Sell
8,223
-1,529
-16% -$174K 0.41% 42
2023
Q1
$1.04M Sell
9,752
-120
-1% -$13K 0.48% 40
2022
Q4
$1.1M Sell
9,872
-6,730
-41% -$688K 0.53% 41
2022
Q3
$1.43M Buy
16,602
+410
+3% +$36.6K 0.72% 36
2022
Q2
$1.48M Buy
16,192
+1,940
+14% +$172K 0.64% 42
2022
Q1
$1.17M Buy
14,252
+7,501
+111% +$591K 0.41% 62
2021
Q4
$518K Buy
+6,751
New +$538K 0.15% 135

Other funds holding MRK

DCM Advisors's MRK Position: Q2 2024 in Review

DCM Advisors sold out of Merck (MRK) in Q2 2024, closing a stake of 4,739 shares — an estimated $625K sold.

DCM Advisors first reported a position in MRK in Q4 2021 and held it in 10 quarters. The position peaked at $1.48M in Q2 2022. 3,545 funds tracked by Wall St. Rank hold MRK as of Q2 2024.

  • DCM Advisors reported no remaining Merck position as of Q2 2024 after selling out during the quarter.
  • DCM Advisors sold 4,739 Merck shares in Q2 2024, an estimated $625K.
  • DCM Advisors first reported a position in Merck in Q4 2021 and held it in 10 quarters.
  • DCM Advisors's Merck position peaked at $1.48M in Q2 2022.
  • 3,545 funds tracked by Wall St. Rank held Merck as of Q2 2024.

Based on DCM Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.